What is Sutro Biopharma's contract liabilities, non-current?

Sutro Biopharma (STRO) reported contract liabilities, non-current of $1.23M in Q1 2026.

How has Sutro Biopharma's contract liabilities, non-current changed year-over-year?

Sutro Biopharma's contract liabilities, non-current decreased by 85.6% year-over-year, from $8.57M to $1.23M.

What is the long-term trend for Sutro Biopharma's contract liabilities, non-current?

Over 4 years (2020 to 2025), Sutro Biopharma's contract liabilities, non-current has grown at a -24.1% compound annual growth rate (CAGR), from $6.1M to $2.03M.

Sutro Biopharma STRO Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

RegenxbioRGNX

——

SchrodingerSDGR

——

CytomX TherapeuticsCTMX

——

Recursion Pharmaceuticals, Inc.RXRX

——

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's contract liabilities, non-current?: Sutro Biopharma (STRO) reported contract liabilities, non-current of $1.23M in Q1 2026.
How has Sutro Biopharma's contract liabilities, non-current changed year-over-year?: Sutro Biopharma's contract liabilities, non-current decreased by 85.6% year-over-year, from $8.57M to $1.23M.
What is the long-term trend for Sutro Biopharma's contract liabilities, non-current?: Over 4 years (2020 to 2025), Sutro Biopharma's contract liabilities, non-current has grown at a -24.1% compound annual growth rate (CAGR), from $6.1M to $2.03M.